Anaeropharma is dedicated toslide_img_5 creating innovative therapies and committed to collaborate with pharmaceutical companies as well as academic institutions in order to jointly discover and develop new drug candidates based on our core technology, i-DPS.

  • We are seeking partnering opportunities to jointly develop our current preclinical projects such as immune checkpoint blocker expressed i-DPS (anti-CTLA4 scFv, anti-PD-1 scFv + anti-CTLA4 scFv) for cancer and FGF2 expressed i-DPS for ischemia.
  • We are able to generate recombinant B. longum which will express any gene of your interest (antibody scFv, cytokine, fusion protein, peptide, etc.) by utilizing our core platform technology, i-DPS.